medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2010, Number S1

<< Back Next >>

Rev Mex Med Transfus 2010; 3 (S1)

Transfusion related immunomodulation

Rodríguez MH

Language: Spanish
References: 33
Page: 24-30
PDF size: 178.08 Kb.


ABSTRACT

Transfusion related immunomodulation (TRIM) is a consequence of the presence in the plasma from cellular components stored in the Blood Bank for variable periods. The storage allows the release of cytokines at a concentration of up to 20 times the level they are at the beginning of this storage. These cytokines are related to the presence of leukocytes, which is why we used the leukoreduction in principle to abate non-hemolytic febrile reactions. The TRIM can have beneficial or harmful effects to the patient eg. tolerance to allogenic kidney transplantation and higher proportion of mortality in transfused patients in Intensive Care Units (30 days) and in greater long-term in patients with major surgery. More information is required from randomized controlled trials to confirm these observations. As this occurs, you should carefully evaluate the indication of pre-storage leukoreduced blood transfusion and in some cases, irradiated blood to eliminate mononuclear cells that persist after leukoreduction.


REFERENCES

  1. Opelz G, Sengar DP, Mickey MR, Terasaky PL. Effect of Blood Transfusion on Subsequent Kidney transplants. Transplant Proc 1973; 5: 253-259.

  2. Vázquez-Salas L. Arellano J. Mac Gregor GJ, Novelo B et al. Inmunosupresión y transfusiones sanguíneas en pacientes con trasplante renal. Gaceta Médica de México 1992; 128: 253-257.

  3. Terasaki PL. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. Transplantation 1984; 37: 119-125.

  4. Lagaaij EL, Hennemann PH, Ruigrok M et al. Effect to one HLA-DR antigen matched and completely HLA-DR mismatched blood transfusions on survival of heart and kidney allografts. N Engl JM 1989; 321: 701-705.

  5. Blumberg N, Heal JM. Transfusion and the immune system, a paradigm shift in progress? Transfusion 1995; 35: 978-883.

  6. Wintrobe MM. Clinical Hematology. Third edition. Lea & Febiger, Philadelphia (EUA), 1951: 861.

  7. Boshkov LK, Furnary A, Morris C, Chien G et al. Prestorage leukoreduction of red cells in elective cardiac surgery. Results of a double-blind randomized controled trial. Blood 2004; 104: 112a (abstract).

  8. Bernstein L, Nathwani B, Shibata D, Sullivan-Halley J, Levine AM. History of transfusion and increased risk of lymphoma in HIV positive men (abstract). Blood 1994; 84: (Suppl): 482 a.

  9. Carson JL, Altman DG, Duff A, Noveck H, Weinstein MP et al. Risk of bacterial infection associated with allogenic blood transfusion among patients undergoing hip fracture repair. Transfusion 199; 39: 694-700.

  10. Aye MT, Palmer DS, Giulini A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995; 35: 117-124.

  11. C hudziak D, Pfeiffer HU, Seifred E, Böning HET. Accumulation of soluble inflammatory mediators between blood donation and prestorage leukocyte depletion. Vox Sang 2009; 96: 163-166.

  12. Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14-17.

  13. Spiess BD, Royston D, Levy JH et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse events. Transfusion 2004; 44: 1143-1148.

  14. Kirkley SA, Cowles J, Pellegrini VD Jr, Harris CM et al. Cytokine secretion after allogenic or autologous blood transfusion (letter) Lancet 1995: 345-527.

  15. Dzik WH, Mincheff M, Puppo F. An alternative mechanism for the immunosupresive effect of transfusion. Vox Sang 2002, 83 (Suppl I): 417-419.

  16. Nusbacher J. Blood transfusion in mononuclear cell transplantation. Transfusion 1994; 34: 1002-1006.

  17. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Page 761 in: Clinical Aspects of Immunology, Gell PGH, Coombs RRA, Lachmann PJ (editors), Blackwell 1975.

  18. Hans S. Thrombo-hemorrhagic phenomena. Charles S. Thomas Publisher. Springfield Illinois. USA 1966: 3-17.

  19. Silliman CC , Boshkov L, Mehdizadehkashi Z, Elzi DJ et al. Transfusion related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101: 454-462.

  20. Bilgin YM, Brand AET. Transfusion related immunomodulation: a second hit in and inflammatory cascade? Vox Sang 2008; 95: 261-371.

  21. Fast LD. Microchimerism: a lasting legacy of transfusion? Transfusion 2006; 46: 1856-1858.

  22. Utter GH, Nathens AB, Lee TH, Reed JT et al. Leukoreduction of blood transfusions does not diminish transfusion-associated microchimerism in trauma patients. Transfusion 2006; 46: 1863-1869.

  23. Dzik WH. Mononuclear cell microchimerism and the immunomodulatory effect of transfusion. Transfusion 1994; 34: 1007-1012.

  24. Pirofsky B. Autoimmunization and the Autoimmune Hemolytic Anemias. The Williams & Wilkins Company Baltimore 1969: 245.

  25. Nelson JL, Your cells are my cells. Scientific American 2008; 298: 64-71.

  26. Heal JM, Phipps RP, Blumberg N. One big unhappy family: Transfusion alloimmunization, thrombosis, and immunomodulation/ inflammation. Transfusion 2009; 49: 1032-1036.

  27. Starzl TE, Demetris AJ, Murase N et al. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579-1582.

  28. Starzl TE, Demetris AJ, Trucco M et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher’s disease. N Engl J Med 1993; 328: 745-749.

  29. Schlitt HJ, Kanehiro H, Raddatz G et al. Persistence of donor lymphocytes in liver allografth recipients. Transplantation 1993; 56: 1001-1007.

  30. Heddle NM. Editorial Universal. Leukoreduction and acute transfusion reactions: putting the puzzle together. Transfusion 2004; 44: 1-4.

  31. Yaser MH, Podlosky L, Clarke G, Nihirmak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44: 10-15.

  32. Nightingale SD. Universal WBC reduction conference report. Transfusion 2001; 41: 1306-309.

  33. Vamvakas E, Blajchman AM. Transfusion related immunomodulation (TRIM): An update. Blood Reviews 2007; 21: 327-348.




2020     |     www.medigraphic.com